Details for Patent: 10,124,132

Which drugs does patent 10,124,132 protect, and when does it expire?

Patent 10,124,132 protects ONZETRA XSAIL and XHANCE and is included in two NDAs.

This patent has five patent family members in three countries.

Summary for Patent: 10,124,132

Title:	Nasal delivery
Abstract:	A nasal delivery device for and method of delivering substance to a nasal cavity of a subject, the delivery device comprising: a nosepiece unit including a nosepiece for fitting to a nostril of a subject and a nozzle through which substance is in use delivered, preferably substantially axially to a longitudinal axis of the nosepiece, to the respective nasal cavity, wherein at least a tip element of the nosepiece has, at least in one configuration, an elongate lateral section which has a longer dimension in a first, sagittal direction than a second direction orthogonal to the sagittal direction, such that, when the nosepiece is inserted in the nasal cavity of the subject, the longer dimension of the nosepiece acts to engage lower and upper surfaces of the nasal cavity, preferably at the nasal valve, and expand the same in the sagittal plane; and a delivery unit for delivering substance through the nozzle of the nosepiece.
Inventor(s):	Djupesland; Per Gisle (Oslo, NO)
Assignee:	OptiNose AS (Oslo, NO)
Application Number:	15/051,622
Patent Claim Types: see list of patent claims	Use; Composition; Delivery; Device;

Drugs Protected by US Patent 10,124,132

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Currax	ONZETRA XSAIL	sumatriptan succinate	POWDER;NASAL	206099-001	Jan 27, 2016		RX	Yes	Yes			Y			ACUTE TREATMENT OF MIGRAINE BY DELIVERING A POWDERED SUBSTANCE COMPRISING SUMATRIPTAN VIA A BREATH-POWERED DELIVERY DEVICE
Currax	ONZETRA XSAIL	sumatriptan succinate	POWDER;NASAL	206099-001	Jan 27, 2016		RX	Yes	Yes			Y			ACUTE TREATMENT OF MIGRAINE
Currax	ONZETRA XSAIL	sumatriptan succinate	POWDER;NASAL	206099-001	Jan 27, 2016		RX	Yes	Yes			Y			TREATMENT OF MIGRAINE VIA DELIVERY OF SUMATRIPTAN VIA THE NASAL CAVITY
Optinose Us Inc	XHANCE	fluticasone propionate	SPRAY, METERED;NASAL	209022-001	Sep 18, 2017		RX	Yes	Yes			Y			METHOD OF DELIVERING FLUTICASONE PROPIONATE TO A NASAL AIRWAY

Foreign Priority and PCT Information for Patent: 10,124,132

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
United Kingdom	0604444.0	Mar 6, 2006

International Family Members for US Patent 10,124,132

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	1996266
United Kingdom	0604444
United Kingdom	0704302
United Kingdom	2435835